Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular
mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced …

Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …

This article refers to 'Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA
Heart Failure Long-Term-Registry: bridging between European Medicines Agency/Food and …

Background: Sacubitril/Valsartan use in heart failure has shown promising results in early
trials. However, the effects on the overall functional capacity, exercise capacity, and quality …

Background Randomized controlled trials (RCT) generalizability may be limited due to strict
patient selection. Objective In a real‐world heart failure (HF) population, we assessed …

Background—The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696)
reduced cardiovascular morbidity and mortality compared with enalapril in patients with …

Aims: In recent large trials, sacubitril/valsartan demonstrated favorable effects in patients
with HF. However, many patients do not achieve the target dose of treatment. This study …

Objectives To determine efficacy and safety of sacubitril/valsartan compared with enalapril in
Indian patients of PARADIGM-HF trial. Methods A randomized, double-blind, active …

Abstract The Prospective Comparison of Angiotensin Receptor Antagonist and Neprilysin
Inhibitor with Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global …

Since initial publication of the PARADIGM‐HF trial in 2014, sacubitril/valsartan has been
investigated in various settings to establish optimal use, further expanding its indications in …